Surgical management of hepatic metastases of colorectal cancer

Hematology/Oncology Clinics of North America

Volumn 29, Issue 1, 2015, Pages 61-84

  Smith, J Joshua ^a   D'Angelica, Michael I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Colorectal liver metastasis; Hepatic arterial infusion; Hepatic resection

Indexed keywords

BEVACIZUMAB; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CHEMOKINE RECEPTOR CXCR4; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; HEMOGLOBIN;

ADJUVANT CHEMOTHERAPY; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL DECISION MAKING; COLORECTAL LIVER METASTASIS; COLORECTAL TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE INTERVAL; ECHOGRAPHY; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; LAPAROSCOPY; LAPAROTOMY; LIVER METASTASIS; LIVER RESECTION; LONG TERM SURVIVAL; LUNG METASTASIS; LUNG RESECTION; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PROGRESSION FREE SURVIVAL; PUBLIC HEALTH PROBLEM; RECURRENCE FREE SURVIVAL; REVIEW; SURGICAL APPROACH; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT RESPONSE; COLORECTAL NEOPLASMS; DISEASE MANAGEMENT; LIVER NEOPLASMS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RETREATMENT; SECONDARY; TREATMENT OUTCOME; TUMOR RECURRENCE;

COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; HUMANS; LIVER NEOPLASMS; MORBIDITY; MORTALITY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETREATMENT; TREATMENT OUTCOME;

EID: 84919359973     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.09.003     Document Type: Review

References (115)

1. Valastyan S., Weinberg R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147(2):275-292.
2. Jemal A., Center M.M., DeSantis C., et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19(8):1893-1907.
3. Siegel R., Ma J., Zou Z., et al. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
4. Tzeng C.W., Aloia T.A. Colorectal liver metastases. JGastrointest Surg 2013, 17(1):195-201. [quiz: 201-2].
5. Fong Y., Fortner J., Sun R.L., et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230(3):309-318. [discussion: 318-21].
6. Stangl R., Altendorf-Hofmann A., Charnley R.M., et al. Factors influencing the natural history of colorectal liver metastases. Lancet 1994, 343(8910):1405-1410.
7. Tomlinson J.S., Jarnagin W.R., DeMatteo R.P., et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. JClin Oncol 2007, 25(29):4575-4580.
8. Foster J.H., Berman M. Solid liver tumors 1977, W.B. Saunders Company, Philadelphia.
9. Scheele J., Stangl R., Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990, 77(11):1241-1246.
10. Choti M.A., Sitzmann J.V., Tiburi M.F., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002, 235(6):759-766.
11. Brouquet A., Abdalla E.K., Kopetz S., et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. JClin Oncol 2011, 29(8):1083-1090.
12. Gallagher D.J., Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology 2010, 78(3-4):237-248.
13. Silen W. Hepatic resection for metastases from colorectal carcinoma is of dubious value. Arch Surg 1989, 124(9):1021-1022.
14. Benson A.B., Bekaii-Saab T., Chan E., et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. JNatl Compr Canc Netw 2013, 11(2):141-152. [quiz: 152].
15. Poultsides G.A., Servais E.L., Saltz L.B., et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. JClin Oncol 2009, 27(20):3379-3384.
16. Auer R.C., White R.R., Kemeny N.E., et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010, 116(6):1502-1509.
17. 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999, 178(4):282-287.
18. 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. JNucl Med 2005, 46(12):2020-2028.
19. Moulton C.A., Gu C.S., Law C.H., et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA 2014, 311(18):1863-1869.
20. Benson A.B., Bekaii-Saab T., Chan E., et al. Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. JNatl Compr Canc Netw 2013, 11(5):519-528.
21. Frankel T.L., D'Angelica M.I. Hepatic resection for colorectal metastases. JSurg Oncol 2014, 109(1):2-7.
22. Ekberg H., Tranberg K.G., Andersson R., et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986, 73(9):727-731.
23. D'Angelica M. Are patients with multiple hepatic metastases from colorectal cancer candidates for surgery? Nature clinical practice. Oncology 2007, 4(12):682-683.
24. Cady B., Stone M.D., McDermott W.V., et al. Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg 1992, 127(5):561-568. [discussion: 568-9].
25. Weber S.M., Jarnagin W.R., DeMatteo R.P., et al. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 2000, 7(9):643-650.
26. Pawlik T.M., Abdalla E.K., Ellis L.M., et al. Debunking dogma: surgery for four or more colorectal liver metastases is justified. JGastrointest Surg 2006, 10(2):240-248.
27. Kornprat P., Jarnagin W.R., Gonen M., et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 2007, 14(3):1151-1160.
28. Malik H.Z., Hamady Z.Z., Adair R., et al. Prognostic influence of multiple hepatic metastases from colorectal cancer. Eur J Surg Oncol 2007, 33(4):468-473.
29. Cady B., Jenkins R.L., Steele G.D., et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 1998, 227(4):566-571.
30. Pawlik T.M., Scoggins C.R., Zorzi D., et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005, 241(5):715-722. [discussion: 722-4].
31. Are C., Gonen M., Zazzali K., et al. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg 2007, 246(2):295-300.
32. DeMatteo R.P., Palese C., Jarnagin W.R., et al. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. JGastrointest Surg 2000, 4(2):178-184.
33. Blumgart L.H., Fong Y. Surgical options in the treatment of hepatic metastasis from colorectal cancer. Curr Probl Surg 1995, 32(5):333-421.
34. Elias D., Liberale G., Vernerey D., et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005, 12(11):900-909.
35. Carpizo D.R., D'Angelica M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Ann Surg Oncol 2009, 16(9):2411-2421.
36. Jarnagin W.R., Fong Y., Ky A., et al. Liver resection for metastatic colorectal cancer: assessing the risk of occult irresectable disease. JAm Coll Surg 1999, 188(1):33-42.
37. Grobmyer S.R., Fong Y., D'Angelica M., et al. Diagnostic laparoscopy prior to planned hepatic resection for colorectal metastases. Arch Surg 2004, 139(12):1326-1330.
38. Bickenbach K.A., Dematteo R.P., Fong Y., et al. Risk of occult irresectable disease at liver resection for hepatic colorectal cancer metastases: a contemporary analysis. Ann Surg Oncol 2013, 20(6):2029-2034.
39. Martin R., Paty P., Fong Y., et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. JAm Coll Surg 2003, 197(2):233-241. [discussion: 241-2].
40. Reddy S.K., Pawlik T.M., Zorzi D., et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 2007, 14(12):3481-3491.
41. Hillingso J.G., Wille-Jorgensen P. Staged or simultaneous resection of synchronous liver metastases from colorectal cancer-a systematic review. Colorectal Dis 2009, 11(1):3-10.
42. Rougier P., Milan C., Lazorthes F., et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Francaise de Cancerologie Digestive. Br J Surg 1995, 82(10):1397-1400.
43. Manfredi S., Lepage C., Hatem C., et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006, 244(2):254-259.
44. Kopetz S., Chang G.J., Overman M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. JClin Oncol 2009, 27(22):3677-3683.
45. House M.G., Ito H., Gonen M., et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. JAm Coll Surg 2010, 210(5):744-752. 752-5.
46. Zakaria S., Donohue J.H., Que F.G., et al. Hepatic resection for colorectal metastases: value for risk scoring systems?. Ann Surg 2007, 246(2):183-191.
47. Kattan M.W., Gonen M., Jarnagin W.R., et al. Anomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg 2008, 247(2):282-287.
48. Takakura Y., Okajima M., Kanemitsu Y., et al. External validation of two nomograms for predicting patient survival after hepatic resection for metastatic colorectal cancer. World J Surg 2011, 35(10):2275-2282.
49. Kattan M.W., Marasco J. What is a real nomogram?. Semin Oncol 2010, 37(1):23-26.
50. Ito H., Mo Q., Qin L.X., et al. Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer. PLoS One 2013, 8(12):e81680.
51. Wong V.K., Malik H.Z., Hamady Z.Z., et al. C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br J Cancer 2007, 96(2):222-225.
52. Kishi Y., Kopetz S., Chun Y.S., et al. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 2009, 16(3):614-622.
53. Katz S.C., Pillarisetty V., Bamboat Z.M., et al. Tcell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol 2009, 16(9):2524-2530.
54. Yopp A.C., Shia J., Butte J.M., et al. CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2012, 19(Suppl 3):S339-S346.
55. Tan M.C., Butte J.M., Gonen M., et al. Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis. HPB (Oxford) 2013, 15(10):803-813.
56. Foster J.H. Survival after liver resection for cancer. Cancer 1970, 26(3):493-502.
57. Aloia T.A., Fahy B.N., Fischer C.P., et al. Predicting poor outcome following hepatectomy: analysis of 2313 hepatectomies in the NSQIP database. HPB (Oxford) 2009, 11(6):510-515.
58. Andres A., Toso C., Moldovan B., et al. Complications of elective liver resections in a center with low mortality: a simple score to predict morbidity. Arch Surg 2011, 146(11):1246-1252.
59. Ito H., Are C., Gonen M., et al. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg 2008, 247(6):994-1002.
60. Matsuda A., Matsumoto S., Seya T., et al. Does postoperative complication have a negative impact on long-term outcomes following hepatic resection for colorectal liver metastasis?: a meta-analysis. Ann Surg Oncol 2013, 20(8):2485-2492.
61. Gold J.S., Are C., Kornprat P., et al. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg 2008, 247(1):109-117.
62. Scheele J., Stang R., Altendorf-Hofmann A., et al. Resection of colorectal liver metastases. World J Surg 1995, 19(1):59-71.
63. Man K., Fan S.T., Ng I.O., et al. Prospective evaluation of Pringle maneuver in hepatectomy for liver tumors by a randomized study. Ann Surg 1997, 226(6):704-711. [discussion: 711-3].
64. Belghiti J., Noun R., Zante E., et al. Portal triad clamping or hepatic vascular exclusion for major liver resection. A controlled study. Ann Surg 1996, 224(2):155-161.
65. Stephenson K.R., Steinberg S.M., Hughes K.S., et al. Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg 1988, 208(6):679-687.
66. Rosen C.B., Nagorney D.M., Taswell H.F., et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 1992, 216(4):493-504. [discussion: 504-5].
67. Kooby D.A., Stockman J., Ben-Porat L., et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003, 237(6):860-869. [discussion: 869-70].
68. Melendez J.A., Arslan V., Fischer M.E., et al. Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. JAm Coll Surg 1998, 187(6):620-625.
69. Jarnagin W.R., Gonen M., Maithel S.K., et al. Aprospective randomized trial of acute normovolemic hemodilution compared to standard intraoperative management in patients undergoing major hepatic resection. Ann Surg 2008, 248(3):360-369.
70. Adson M.A., van Heerden J.A., Adson M.H., et al. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984, 119(6):647-651.
71. McCormack P.M., Burt M.E., Bains M.S., et al. Lung resection for colorectal metastases. 10-year results. Arch Surg 1992, 127(12):1403-1406.
72. Miller G., Biernacki P., Kemeny N.E., et al. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. JAm Coll Surg 2007, 205(2):231-238.
73. Maithel S.K., Ginsberg M.S., D'Amico F., et al. Natural history of patients with subcentimeter pulmonary nodules undergoing hepatic resection for metastatic colorectal cancer. JAm Coll Surg 2010, 210(1):31-38.
74. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013, 14(12):1208-1215.
75. Primrose J., Falk S., Finch-Jones M., et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014, 15(6):601-611.
76. Ensminger W.D., Rosowsky A., Raso V., et al. Aclinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res 1978, 38(11 Pt 1):3784-3792.
77. Kemeny N., Jarnagin W., Gonen M., et al. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. JClin Oncol 2003, 21(17):3303-3309.
78. Kemeny N.E., Gonen M. Hepatic arterial infusion after liver resection. NEngl J Med 2005, 352(7):734-735.
79. Sigurdson E.R., Ridge J.A., Kemeny N., et al. Tumor and liver drug uptake following hepatic artery and portal vein infusion. JClin Oncol 1987, 5(11):1836-1840.
80. House M.G., Kemeny N.E., Gonen M., et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg 2011, 254(6):851-856.
81. Kemeny N.E., Jarnagin W.R., Capanu M., et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. JClin Oncol 2011, 29(7):884-889.
82. Ito K., Ito H., Kemeny N.E., et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol 2012, 19(5):1609-1617.
83. Gallagher D.J., Zheng J., Capanu M., et al. Response to neoadjuvant chemotherapy does not predict survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol 2009, 16(7):1844-1851.
84. Neumann U.P., Thelan A., Rocken C., et al. Nonresponse to preoperative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases. Surgery 2009, 146(1):52-59.
85. Gruenberger B., Tamandl D., Schueller J., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. JClin Oncol 2008, 26(11):1830-1835.
86. Mitry E., Fields A.L., Bleiberg H., et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. JClin Oncol 2008, 26(30):4906-4911.
87. Ychou M., Hohenberger W., Thezenas S., et al. Arandomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009, 20(12):1964-1970.
88. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371(9617):1007-1016.
89. Brouquet A., Zimmitti G., Kopetz S., et al. Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases. Cancer 2013, 119(15):2778-2788.
90. Poultsides G.A., Bao F., Servais E.L., et al. Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. Ann Surg Oncol 2012, 19(9):2797-2804.
91. Benoist S., Brouquet A., Penna C., et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. JClin Oncol 2006, 24(24):3939-3945.
92. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. JClin Oncol 2006, 24(13):2065-2072.
93. Jarnagin W.R., Conlon K., Bodniewicz J., et al. Aclinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer 2001, 91(6):1121-1128.
94. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004, 240(4):644-657. [discussion: 657-8].
95. Adam R., Avisar E., Ariche A., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001, 8(4):347-353.
96. Bismuth H., Adam R., Levi F., et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996, 224(4):509-520. [discussion: 520-2].
97. Jones R.P., Hamann S., Malik H.Z., et al. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur J Cancer 2014, 50(9):1590-1601.
98. Kemeny N.E., Melendez F.D., Capanu M., et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. JClin Oncol 2009, 27(21):3465-3471.
99. Vaillant J.C., Balladur P., Nordlinger B., et al. Repeat liver resection for recurrent colorectal metastases. Br J Surg 1993, 80(3):340-344.
100. Lange J.F., Leese T., Castaing D., et al. Repeat hepatectomy for recurrent malignant tumors of the liver. Surg Gynecol Obstet 1989, 169(2):119-126.
101. Hohenberger P., Schlag P., Schwarz V., et al. Tumor recurrence and options for further treatment after resection of liver metastases in patients with colorectal cancer. JSurg Oncol 1990, 44(4):245-251.
102. Griffith K.D., Sugarbaker P.H., Chang A.E. Repeat hepatic resections for colorectal metastases. Surgery 1990, 107(1):101-104.
103. Butler J., Attiyeh F.F., Daly J.M. Hepatic resection for metastases of the colon and rectum. Surg Gynecol Obstet 1986, 162(2):109-113.
104. Bozzetti F., Bignami P., Montalto F., et al. Repeated hepatic resection for recurrent metastases from colorectal cancer. Br J Surg 1992, 79(2):146-148.
105. Fortner J.G. Recurrence of colorectal cancer after hepatic resection. Am J Surg 1988, 155(3):378-382.
106. Nordlinger B., Quilichini M.A., Parc R., et al. Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrences in 80 patients. Ann Surg 1987, 205(3):256-263.
107. Fong Y., Blumgart L.H., Cohen A., et al. Repeat hepatic resections for metastatic colorectal cancer. Ann Surg 1994, 220(5):657-662.
108. Pinson C.W., Wright J.K., Chapman W.C., et al. Repeat hepatic surgery for colorectal cancer metastasis to the liver. Ann Surg 1996, 223(6):765-773. [discussion: 773-6].
109. Petrowsky H., Gonen M., Jarnagin W., et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002, 235(6):863-871.
110. Hughes K.S., Simon R., Songhorabodi S., et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986, 100(2):278-284.
111. Scheele J., Stangl R., Altendorf-Hofmann A., et al. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991, 110(1):13-29.
112. Gayowski T.J., Iwatsuki S., Madariaga J.R., et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 1994, 116(4):703-710.
113. Nordlinger B., Guiguet M., Vaillant J.C., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996, 77(7):1254-1262.
114. Jamison R.L., Donohue J.H., Nagorney D.M., et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997, 132(5):505-510.
115. Abdulla E.K., Vauthey J.N., Ellis L.M., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004, 239(6):818-825.